SAN FRANCISCO, CA, Aug 18, 2010 (MARKETWIRE via COMTEX) --
Urigen Pharmaceuticals, Inc. (OTCQB: URGP), a specialty
pharmaceutical company focused on the development of treatments for
urological disorders and pain, announced today that the FDA has
granted the Company a Type C meeting to discuss guidance for clinical
protocols of URG101, a regional therapy for Painful Bladder
Lowell Parsons, MD, Urigen's Chief Medical Officer, said, "We are
pleased the FDA has agreed to meet to discuss our URG101 program.
Since Painful Bladder Syndrome/Interstitial Cystitis occurs in a
discrete region of the body, there is a definite role for a regional
therapy such as URG101, and it may also provide the safest approach."
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic
products for urological disorders. Urigen's two lead programs target
significant unmet medical needs and major market opportunities in
urology. Urigen's URG101, a proprietary combination of approved drugs
that is instilled into the bladder, targets painful bladder syndrome,
which affects approximately 10.5 million men and women in North
America. Urigen's URG301, a proprietary dosage form of an approved
drug that is locally delivered to control urinary urgency, targets
acute urgency in females diagnosed with an overactive bladder,
another major unmet need that is insufficiently managed by presently
available overactive bladder drugs. For further information, please
visit Urigen's website at http://www.urigen.com.
This press release may contain forward-looking statements. These
statements may be identified by the use of forward-looking
terminology such as "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "might," "plan," "potential,"
"predict," "should," or "will," or the negative thereof or other
variations thereon or comparable terminology. Urigen has based these
forward-looking statements on current expectations, assumptions,
estimates and projections. While Urigen believes that these
expectations, assumptions, estimates and projections are reasonable,
such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond
its control. Given these risks and uncertainties, investors and
security holders are cautioned not to place undue reliance on such
forward-looking statements. Urigen does not undertake any obligation
to update any such statements or to publicly announce the results of
any revisions to any such statements to reflect future events or
SOURCE: Urigen Pharmaceuticals, Inc.